ArticleInternational journal of molecular sciences2020
Photoswitchable Azo- and Diazocine-Functionalized Derivatives of the VEGFR-2 Inhibitor Axitinib.
Article in International journal of molecular sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 43 citations in OpenAlex.
- Recent Advances of Azobenzene-Based Photoresponsive Molecular Switches for Protein-Targeted Photopharmacology.Molecules (Basel, Switzerland) · 2026Review
- Optogenetics with Atomic Precision─A Comprehensive Review of Optical Control of Protein Function through Genetic Code Expansion.Chemical reviews · 2025Review
- Solvates and Polymorphs of Axitinib: Characterization and Phase Transformation.Molecules (Basel, Switzerland) · 2024Article
- The antioxidant and antimicrobial activity of ethanolic extract in roots, stems, and leaves of three commercial Cymbopogon species.BMC complementary medicine and therapies · 2024Article
- Triplet sensitization enables bidirectional isomerization of diazocine with 130 nm redshift in excitation wavelengths.Chemical science · 2023Article
- Photoswitchable Inhibitors to Optically Control Specific Kinase Activity.ACS chemical biology · 2023Article
- StilleRSC advances · 2023Article
- Photoresponsive Small Molecule Inhibitors for the Remote Control of Enzyme Activity.Chemistry, an Asian journal · 2022Review
- Light-Control over Casein Kinase 1δ Activity with Photopharmacology: A Clear Case for Arylazopyrazole-Based Inhibitors.International journal of molecular sciences · 2022Article
- Protein Kinases: Function, Substrates, and Implication in Diseases.International journal of molecular sciences · 2022Article
- Optical Fibre-Enabled Photoswitching for Localised Activation of an Anti-Cancer Therapeutic Drug.International journal of molecular sciences · 2021Article
- Controlling the Covalent Reactivity of a Kinase Inhibitor with Light.Angewandte Chemie (International ed. in English) · 2021Article
- Review
- Active Ester Functionalized Azobenzenes as Versatile Building Blocks.Molecules (Basel, Switzerland) · 2021Article
- Substituted nitrogen-bridged diazocines.Beilstein journal of organic chemistry · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
Abstract
In this study, we aimed at the application of the concept of photopharmacology to the approved vascular endothelial growth factor receptor (VEGFR)-2 kinase inhibitor axitinib. In a previous study, we found out that the photoisomerization of axitinib's stilbene-like double bond is unidirectional in aqueous solution due to a competing irreversible [2+2]-cycloaddition. Therefore, we next set out to azologize axitinib by means of incorporating azobenzenes as well as diazocine moieties as photoresponsive elements. Conceptually, diazocines (bridged azobenzenes) show favorable photoswitching properties compared to standard azobenzenes because the thermodynamically stable
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.